| Literature DB >> 31157166 |
Yarely M Salinas-Vera1, Dolores Gallardo-Rincón2, Raúl García-Vázquez3, Olga N Hernández-de la Cruz1, Laurence A Marchat3, Juan Antonio González-Barrios4, Erika Ruíz-García2, Carlos Vázquez-Calzada5, Estefanía Contreras-Sanzón1, Martha Resendiz-Hernández1, Horacio Astudillo-de la Vega6, José L Cruz-Colin7, Alma D Campos-Parra8, César López-Camarillo1.
Abstract
Vasculogenic mimicry (VM) is a novel cancer hallmark in which malignant cells develop matrix-associated 3D tubular networks with a lumen under hypoxia to supply nutrients needed for tumor growth. Recent studies showed that microRNAs (miRNAs) may have a role in VM regulation. In this study, we examined the relevance of hypoxia-regulated miRNAs (hypoxamiRs) in the early stages of VM formation. Data showed that after 48 h hypoxia and 12 h incubation on matrigel SKOV3 ovarian cancer cells undergo the formation of matrix-associated intercellular connections referred hereafter as 3D channels-like structures, which arose previous to the apparition of canonical tubular structures representative of VM. Comprehensive profiling of 754 mature miRNAs at the onset of hypoxia-induced 3D channels-like structures showed that 11 hypoxamiRs were modulated (FC>1.5; p < 0.05) in SKOV3 cells (9 downregulated and 2 upregulated). Bioinformatic analysis of the set of regulated miRNAs showed that they might impact cellular pathways related with tumorigenesis. Moreover, overall survival analysis in a cohort of ovarian cancer patients (n = 485) indicated that low miR-765, miR-193b, miR-148a and high miR-138 levels were associated with worst patients outcome. In particular, miR-765 was severely downregulated after hypoxia (FC < 32.02; p < 0.05), and predicted to target a number of protein-encoding genes involved in angiogenesis and VM. Functional assays showed that ectopic restoration of miR-765 in SKOV3 cells resulted in a significant inhibition of hypoxia-induced 3D channels-like formation that was associated with a reduced number of branch points and patterned tubular-like structures. Mechanistic studies confirmed that miR-765 decreased the levels of VEGFA, AKT1 and SRC-α transducers and exerted a negative regulation of VEGFA by specific binding to its 3'UTR. Finally, overall survival analysis of a cohort of ovarian cancer patients (n = 1435) indicates that high levels of VEGFA, AKT1 and SRC-α and low miR-765 expression were associated with worst patients outcome. In conclusion, here we reported a novel hypoxamiRs signature which constitutes a molecular guide for further clinical and functional studies on the early stages of VM. Our data also suggested that miR-765 coordinates the formation of 3D channels-like structures through modulation of VEGFA/AKT1/SRC-α axis in SKOV3 ovarian cancer cells.Entities:
Keywords: VEGFA; hypoxia; miR-765; ovarian cancer; vasculogenic mimicry
Year: 2019 PMID: 31157166 PMCID: PMC6528691 DOI: 10.3389/fonc.2019.00381
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 13D channels-like formation in SKOV3 ovarian cancer cells. (A-F) SKOV3 cells were previously incubated onto matrigel with serum free medium for 12 h (time 0), and then imaged during course of time (0–12 h) as showed in (A-C) normoxia and (D-F) hypoxia conditions. Arrows denote the capillary-like tubes. Arrowheads denote the branch points. (G) Graphical representation of quantification of cellular networks and (H) branch points number after 0, 6, and 12 h. Experiments were performed three times by triplicate and data were expressed as mean ± S.D. ***p < 0.001. (I) Bright field images (10×) and (J) Periodic acid-Schiff (PAS) stained images (10×) of cultures on matrigel. (K-O) Images of 3D-culture observed under confocal laser-scanning microscopy. Cells in (K,M) clear field and stained with (L,N,O) rhodamine-phalloidin. (O) Confocal microscopy Z-stack reconstruction of cellular networks.
Figure 2MicroRNAs deregulated in SKOV3 cells after 48 h hypoxia. Upper Table illustrate the hypoxamiRs regulated in SKOV3 cells. The miRNAs expression status and clinical value predicted after Kaplan Meir analysis is depicted. Bottom Images showed the Kaplan Meir plots for four hypoxamiRs with potential clinical value using Start miRpower for pan-cancer as implemented in the KM plotter online tool (http://kmplot.com/analysis/index.php?p=backgroundr).
Figure 3Core miRNA/mRNA interaction networks. (A). Supervised hierarchical clustering of signaling pathways affected by deregulated miRNAs. MicroT-CDS function and Euclidean correlation were used; a p < 0.05 was considered to identify significantly differentially expressed miRNAs in SKOV3 cells after 48 h in hypoxia. Columns display the clustering of cellular pathways. Rows indicate the clustering of miRNAs names, and pathways are denoted at bottom. (B) Illustration depicts the modulated miRNAs after 48 h of hypoxia and predicted target mRNAs involved in angiogenesis and vasculogenic mimicry.
Modulated microRNAs after 48 h hypoxia in SKOV3 ovarian cancer cells and predicted targets with functions associated to cancer.
| miR-486-3p | HIF1AN | Hypoxia inducible factor 1 alpha subunit inhibitor | Oxygen sensor | Kang et al. ( |
| SRCIN1 | SRC kinase signaling inhibitor 1 | Inhibitor of AKT/RAS pathway | ||
| miR-138 | FAM13 | Fas apoptotic inhibitory molecule 3 | Inhibitor of RAS pathway | Kang et al. ( |
| PTGFRN | Prostaglandin F2 receptor inhibitor | Inhibitor of angiogenesis, VM | Colin et al. ( | |
| HIF1AN | Hypoxia inducible factor 1 alpha subunit inhibitor | Oxygen sensor | ||
| miR-765 | VEGFA | Vascular endothelial growth factor A | Angiogenesis, proliferation, VM | Chen et al. ( |
| AKT1 | RAC-alpha serine/threonine-protein kinase | Angiogenesis, proliferation, migration, VM | Rana et al. ( | |
| HIF-3A | Hypoxia inducible factor 3 alpha | Angiogenesis, VM | Li et al. ( | |
| PDGFR | Platelet-derived growth factor receptor | Proliferation, angiogenesis, migration | Wei et al. ( | |
| TGFBR2 | Transforming growth factor, beta receptor II | Proliferation, differentiation, angiogenesis, VM | Salinas-Vera et al. ( | |
| MMP2 | Matrix metallopeptidase 2 | Angiogenesis, metastasis, VM | Ando et al. ( | |
| Cuomo et al. ( | ||||
| Avril et al. ( | ||||
| Thijssen et al. ( | ||||
| Plantamura et al. ( | ||||
| Khalkhali-Ellis et al. ( | ||||
| Kang et al. ( | ||||
| Liang et al. ( | ||||
| miR-660 | VEGFA | Vascular endothelial growth factor A | Angiogenesis, proliferation, VM | Luengo-Gil et al. ( |
| SRC | Proto-oncogene tyrosine-protein kinase | Proliferation, migration, VM | Salinas-Vera et al. ( | |
| HIF-1A | Hypoxia inducible factor 1, alpha | Angiogenesis, VM | Jaraíz et al. ( | |
| TGFBR2 | Transforming growth factor, beta receptor II | Proliferation, differentiation, VM. | Chen et al. ( | |
| PDGFR2 | Platelet-derived growth factor receptor | Proliferation, differentiation, VM | Rana et al. ( | |
| Plantamura et al. ( | ||||
| Khalkhali-Ellis et al. ( | ||||
| Avril et al. ( | ||||
| Thijssen et al. ( | ||||
| miR-218 | SHC1 | SHC-transforming protein 1 | Proliferation, angiogenesis, VM | Salinas-Vera et al. ( |
| CDH8 | Cadherin-8 | Migration | Thomas et al. ( | |
| Memi et al. ( | ||||
| miR-198 | SRC | Proto-oncogene tyrosine-protein kinase | Proliferation, migration, VM | Salinas-Vera et al. ( |
| SHC1 | SHC-transforming protein 1 | Proliferation, angiogenesis, VM | Jaraíz et al. ( | |
| HIF-3A | Hypoxia inducible factor 3, alpha subunit | Angiogenesis, VM | Thomas et al. ( | |
| PTK2 | Focal adhesion kinase 1 | Proliferation, migration, VM | Suen et al. ( | |
| Ando et al. ( | ||||
| Cuomo et al. ( | ||||
| miR-518b | MAPK1 | Mitogen-activated protein kinase 1 | Angiogenesis, proliferation, VM | Wei et al. ( |
| TGFBR2 | Transforming growth factor, beta receptor II | Proliferation, differentiation, angiogenesis, VM | Flum et al. ( | |
| Plantamura et al. ( | ||||
| Khalkhali-Ellis et al. ( | ||||
| miR-148a | TGFBR2 | Transforming growth factor, beta receptor II | Proliferation, differentiation, angiogenesis, VM | Plantamura et al. ( |
| MMP16 | Matrix metallopeptidase 16 | Angiogenesis, metastasis | Khalkhali-Ellis et al. ( | |
| HIF-3A | Hypoxia inducible factor 3 alpha subunit | Angiogenesis, VM | Kang et al. ( | |
| Li et al. ( | ||||
| Ando et al. ( | ||||
| Cuomo et al. ( | ||||
| miR-1290 | VEGFA | Vascular endothelial growth factor A | Angiogenesis, proliferation, VM | Chen et al. ( |
| PTK2 | Focal adhesion kinase 1 | Proliferation, migration, VM | Rana et al. ( | |
| SRC | Proto-oncogene tyrosine-protein kinase | Proliferation, migration, VM | Luengo-Gil et al. ( | |
| HIF-1A | Hypoxia inducible factor 1 alpha | Angiogenesis, VM | Salinas-Vera et al. ( | |
| TGFBR2 | Transforming growth factor, beta receptor II | Proliferation, differentiation, angiogenesis, VM | Jaraíz et al. ( | |
| Chen et al. ( | ||||
| Rana et al. ( | ||||
| Plantamura et al. ( | ||||
| Khalkhali-Ellis et al. ( | ||||
| miR-193b | SHC3 | SHC-transforming protein 3 | Proliferation, angiogenesis, VM | Liu Y et al. ( |
| GRB2 | Growth factor receptor-bound protein 2 | Proliferation, angiogenesis, VM | Salinas-Vera et al. ( | |
| CDH4 | Cadherin 4, type 1 | Angiogenesis, VM | Zhang et al. ( | |
| HIF3A | Hypoxia inducible factor 3 alpha subunit | Angiogenesis, VM | Xie et al. ( | |
| Ando et al. ( | ||||
| Cuomo et al. ( | ||||
| miR-222 | VEGFB | Vascular endothelial growth factor B | Angiogenesis, proliferation, VM | Chen et al. ( |
| VEGFC | Vascular endothelial growth factor C | Angiogenesis, proliferation, VM | Rana et al. ( | |
| SHC4 | SHC-transforming protein 4 | Proliferation, angiogenesis, VM | Ikeda et al. ( | |
| HIF1A | Hypoxia inducible factor 1, alpha subunit | Angiogenesis, VM | Thomas et al. ( | |
| Suen et al. ( | ||||
| Chen et al. ( | ||||
| Rana et al. ( | ||||
Uniprot database name; VM, vasculogenic mimicry.
Figure 4miR-765 inhibits hypoxia-induced 3D channels-like structures. (A) 3D channels-like structures of SKOV3 cells transfected with miR-765 mimics (right panel), scramble (middle panel) and no-transfected control cells (left panel) and grown for 48 h in hypoxia and then 12 h in matrigel. (B) Graphical representation of the number of branch points and capillary-like channels from (A). (C) Cell viability assays of SKOV3 cells transfected with increasing concentrations of miR-765. Experiments were performed by three times by triplicate and data were expressed as mean ± S.D. ***p < 0.001. NS, non-significant.
Figure 5miR-765 downregulates VEGFA, AKT1 and SRC-α proteins and target VEGFA. (A) Immunoblots of whole proteins extracts (30 μg) from SKOV3 cells grown in normoxia or hypoxia (48 h) using specific antibodies against VEGFA, AKT1, and SRC-α. GADPH was used as loading control. Lane 1, SKOV3 cells in normoxia; lane 2, non-transfected control cells and incubated in hypoxia; lane 3, cells transfected with scramble control and incubated in hypoxia; lane 4, cells transfected with miR-765 mimics and incubated in hypoxia. (B–D) Densitometric quantification of immunodetected bands in panel A. Experiments were performed by triplicate and data were expressed as mean ± S.D. (E) Schematic representation of p-miR report construct containing the 3′UTR of VEGFA gene cloned downstream of luciferase gene. Seed sequence is indicated in colored blue box. Point mutations in the miR-765 binding sites of 3′UTR of VEGFA gene is denoted in bold. Mutations in seed sequence are denoted in bold letters. (F) Luciferase assays in SKOV3 cells transfected with miR-765 mimics and wild type or mutated constructs described in panel E. Cells transfected with p-miR report plasmid alone or with scramble were used as controls. Data represent the mean ± S.D. of three independent experiments.
Figure 6Kaplan-Meier curves for overall survival according the expression of miR-765, VEGFA, AKT1 and SRC-α. Overall survival analysis using Kaplan Meier plotter for (A) miR-765, (B) VEGFA, (C) AKT1, and (D) SRC-α genes. Start KM plotter for ovarian cancer tool used genome-wide for mRNA expression data and overall survival clinical information of cancer patients, which were downloaded from Gene Expression Omnibus GEO (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 plus 2.0 microarrays) and The Cancer Genome Atlas TCGA, whereas for miRNAs expression we used Start miRpower for pan-cancer as implemented in the KM plotter. Samples were split into two groups according to various quantile expression of miR-765 (n = 485) and VEGFA, AKT1 and SRC-α genes in ovarian cancer patients (n = 1435). Kaplan-Meier survival plots compared the two patient cohorts, and the hazard ratio with 95% confidence intervals and logrank P-value were calculated.